[go: up one dir, main page]

MX2012013178A - Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics. - Google Patents

Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.

Info

Publication number
MX2012013178A
MX2012013178A MX2012013178A MX2012013178A MX2012013178A MX 2012013178 A MX2012013178 A MX 2012013178A MX 2012013178 A MX2012013178 A MX 2012013178A MX 2012013178 A MX2012013178 A MX 2012013178A MX 2012013178 A MX2012013178 A MX 2012013178A
Authority
MX
Mexico
Prior art keywords
therapeutically effective
effective quantity
nitazoxanide
prebiotics
probiotics
Prior art date
Application number
MX2012013178A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Priority to MX2012013178A priority Critical patent/MX2012013178A/en
Priority to UY0001035037A priority patent/UY35037A/en
Priority to ARP130103932A priority patent/AR093252A1/en
Priority to PCT/IB2013/060089 priority patent/WO2014076638A1/en
Priority to BR112015010651A priority patent/BR112015010651A2/en
Publication of MX2012013178A publication Critical patent/MX2012013178A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/719—Pullulans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a pharmaceutical composition, preferably oral, used as an anti-parasitic and anti-diarrheal agent comprising a therapeutically effective quantity of the compound nitazoxanide and a therapeutically effective quantity of a probiotic together with pharmaceutically acceptable excipients; and optionally, a therapeutically effective quantity of a prebiotic. The invention also relates to medical uses and methods for producing a pharmaceutical composition used as an anti-parasitic and anti-diarrheal agent comprising a therapeutically effective quantity of the compound nitazoxanide and a therapeutically effective quantity of a probiotic together with pharmaceutically acceptable excipients; and optionally, a therapeutically effective quantity of a prebiotic.
MX2012013178A 2012-11-13 2012-11-13 Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics. MX2012013178A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2012013178A MX2012013178A (en) 2012-11-13 2012-11-13 Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.
UY0001035037A UY35037A (en) 2012-11-13 2013-09-17 ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS
ARP130103932A AR093252A1 (en) 2012-11-13 2013-10-28 ORAL PHARMACEUTICAL COMPOSITION USED AS ANTIPARASITARY AND ANTIDIARRICS AND PROCESSES TO PREPARE IT
PCT/IB2013/060089 WO2014076638A1 (en) 2012-11-13 2013-11-12 Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics
BR112015010651A BR112015010651A2 (en) 2012-11-13 2013-11-12 broad spectrum antiparasitic composition of nitazoxanide, probiotics and prebiotics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012013178A MX2012013178A (en) 2012-11-13 2012-11-13 Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.

Publications (1)

Publication Number Publication Date
MX2012013178A true MX2012013178A (en) 2014-05-22

Family

ID=50730662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013178A MX2012013178A (en) 2012-11-13 2012-11-13 Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.

Country Status (5)

Country Link
AR (1) AR093252A1 (en)
BR (1) BR112015010651A2 (en)
MX (1) MX2012013178A (en)
UY (1) UY35037A (en)
WO (1) WO2014076638A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110279118A (en) * 2019-06-14 2019-09-27 浙江大学宁波理工学院 A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method
CN114158735A (en) * 2021-12-06 2022-03-11 青岛东海药业有限公司 Probiotic composition and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108085265B (en) * 2016-11-22 2021-09-28 北京大北农科技集团股份有限公司 Bacillus coagulans new strain, and microecological preparation and feed thereof
GB201708932D0 (en) * 2017-06-05 2017-07-19 Probi Ab Microbial compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110279118A (en) * 2019-06-14 2019-09-27 浙江大学宁波理工学院 A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method
CN110279118B (en) * 2019-06-14 2022-09-13 浙江大学宁波理工学院 Composite probiotic composition, composite probiotic freeze-dried powder capsule and preparation method
CN114158735A (en) * 2021-12-06 2022-03-11 青岛东海药业有限公司 Probiotic composition and application thereof
CN114158735B (en) * 2021-12-06 2024-05-31 青岛东海药业有限公司 Probiotic composition and application thereof

Also Published As

Publication number Publication date
AR093252A1 (en) 2015-05-27
UY35037A (en) 2014-05-30
BR112015010651A2 (en) 2017-07-11
WO2014076638A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
MX2021000550A (en) Tofacitinib oral sustained release dosage forms.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY163083A (en) Solid forms of a pharmaceutically active substance
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX348823B (en) Stable formulations of linaclotide.
IN2013MU03583A (en)
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2012174158A3 (en) Administration of benzodiazepine
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SV2016005236A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN
MY194495A (en) Compositions and methods for transmucosal absorption
MX359288B (en) Ivabradine hydrochloride form iv.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
PH12012502082A1 (en) Combination of active loaded granules with additional actives
TN2015000135A1 (en) Modified release formulations for oprozomib
MX2015005762A (en) Co-micronisation product comprising ulipristal acetate.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2012013178A (en) Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.
MX2016007682A (en) Pharmaceutical composition comprising amorphous ivabradine.
IN2013MU01177A (en)
MY197454A (en) Non-enteric pharmaceutical composition comprising crofelemer
TN2015000156A1 (en) Dispersible tablet
MX2011005899A (en) Pharmaceutical composition with non-sedative antihistamine and combinations thereof.